Clinisoothe

Clinisoothe markets a single core line: antimicrobial skin-protection sprays and serums sold under the “Clinisoothe+” label. Products span 100 ml daily-use mists down to 30 ml targeted serums, priced £12–£25, placing the range in the accessible-to-mid segment of clinical skincare. Distribution is DTC-first through the brand’s own site, supported by Amazon UK and a selective network of pharmacies, aesthetic clinics and dermatology practices. The formulas are built around high-purity hypochlorous acid (HOCl) produced via proprietary electrochemical activation; the result is a pH-balanced, alcohol-free solution that claims 99.9 % pathogen reduction within 60 seconds while remaining non-cytotoxic to human cells. Clinisoothe positions itself as “skin’s immune system in a bottle,” bridging post-procedure aftercare and everyday anti-pollution defence; the 100 ml Mist has become a cult item among facialists for calming microneedling, laser and acne extractions. Core buyers are 20-45-year-old UK consumers who self-identify as “skin science believers”: they follow dermatologists on social, invest in clinical treatments and want evidence-based aftercare that is gentle enough for daily use. The brand’s cruelty-free, vegan and fragrance-free credentials resonate with clean-beauty values, while the clinical packaging appeals to minimalists who distrust multi-step routines. Clinisoothe competes in the post-procedural/antimicrobial segment against chlorhexidine, benzoyl-peroxide and colloidal-silver brands, but differentiates by offering broad-spectrum antimicrobial action without stinging, staining or antibiotic resistance risk. By focusing on a single hero molecule and publishing independent in-vitro data, it presents itself as a modern, science-over-hype alternative to legacy first-aid antiseptics and complicated multi-acid toners.